Neuroprotective Efficacy of Prophylactic Antiepileptic Therapies in Busulfan Conditioning Regimen

ÇOKYAMAN T., Elli M., Aydin O. F., Albayrak C., Albayrak D., ozyurek E.

JOURNAL OF PEDIATRIC NEUROLOGY, cilt.19, sa.04, ss.235-239, 2021 (ESCI) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 19 Sayı: 04
  • Basım Tarihi: 2021
  • Doi Numarası: 10.1055/s-0040-1708833
  • Dergi Adı: JOURNAL OF PEDIATRIC NEUROLOGY
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, CAB Abstracts, CINAHL, EMBASE
  • Sayfa Sayıları: ss.235-239
  • Anahtar Kelimeler: antiepileptic prophylaxis, busulfan, levetiracetam, STEM-CELL TRANSPLANTATION, HIGH-DOSE BUSULFAN, INTRAVENOUS BUSULFAN, PEDIATRIC BLOOD, PHARMACOKINETICS, CHILDREN, LEVETIRACETAM, LORAZEPAM, SEIZURES, INFUSION
  • Ondokuz Mayıs Üniversitesi Adresli: Evet

Özet

Busulfan (BU) is commonly used in the anticancer treatment and bone marrow/hematopoietic stem cell transplantation (BM/HSCT) conditioning regimen. This study aimed to evaluate the neuroprotective efficacy of antiepileptic therapies in the BU conditioning regimen. Patientswho underwent BM/HSCT betweenJanuary 1, 2009, and January 1,2014, were evaluated retrospectively. Diagnosis, demographic characteristics, neurological side effects, electroencephalography (EEG) abnormalities, and antiepileptic drugs were determined. Levetiracetam was given to 49% and phenytoin to 23% of patients as antiepileptic prophylaxis. After BU treatment, seizures developed in three patients, posterior reversible leukoencephalopathy in twopatients, and peripheral neuropathy in twopatients. Forty-five patients who underwent EEG before and after BU treatment were identified. The effects of antiepileptic prophylaxis over the electroencephalographic abnormalities after the BU conditioning regimen were found to be not different (p = 0.491). Neurological side effects and electroencephalographic abnormalities following BU conditioning regimen under antiepileptic prophylaxis are comparable.